Cargando…
Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study
BACKGROUND: Timely diagnosis and treatment of stage 3 chronic kidney disease (CKD) can prevent further loss of kidney function and progression to kidney failure. However, contemporary data on the global prevalence of undiagnosed stage 3 CKD are scarce. REVEAL-CKD is a multinational, multifocal and o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967537/ https://www.ncbi.nlm.nih.gov/pubmed/35371463 http://dx.doi.org/10.1093/ckj/sfab235 |
_version_ | 1784678862735540224 |
---|---|
author | Kushner, Pamela Peach, Emily Wittbrodt, Eric Barone, Salvatore Chen, Hungta Sanchez, Juan Jose Garcia Järbrink, Krister Arnold, Matthew Tangri, Navdeep |
author_facet | Kushner, Pamela Peach, Emily Wittbrodt, Eric Barone, Salvatore Chen, Hungta Sanchez, Juan Jose Garcia Järbrink, Krister Arnold, Matthew Tangri, Navdeep |
author_sort | Kushner, Pamela |
collection | PubMed |
description | BACKGROUND: Timely diagnosis and treatment of stage 3 chronic kidney disease (CKD) can prevent further loss of kidney function and progression to kidney failure. However, contemporary data on the global prevalence of undiagnosed stage 3 CKD are scarce. REVEAL-CKD is a multinational, multifocal and observational study aiming to provide insights into undiagnosed stage 3 CKD in a large population. METHODS: Patients (aged ≥18 years) with data in selected secondary databases from 11 countries will be included if they have at least two estimated glomerular filtration rate (eGFR) measurements from 2015 onwards that are ≥30 and <60 mL/min/1.73 m(2), recorded >90 and ≤730 days apart. Undiagnosed cases are those without an International Classification of Diseases 9/10 diagnosis code for CKD (any stage) any time before and up to 6 months after the second qualifying eGFR measurement. Time to diagnosis will be assessed using a Kaplan–Meier approach; patient characteristics associated with undiagnosed CKD will be assessed using adjusted logistical regression analyses. RESULTS: REVEAL-CKD will assess the point prevalence of undiagnosed stage 3 CKD and time to CKD diagnosis in initially undiagnosed cases overall and in individual countries. Trends in undiagnosed CKD prevalence by calendar year will be assessed. Patient characteristics, healthcare resource utilization, adverse clinical outcomes, and CKD management and monitoring practices in patients with versus without a CKD diagnosis will be compared. CONCLUSIONS: REVEAL-CKD will increase awareness of the global clinical and economic burden of undiagnosed stage 3 CKD and provide valuable insights to inform clinical practice and policy changes. |
format | Online Article Text |
id | pubmed-8967537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-89675372022-03-31 Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study Kushner, Pamela Peach, Emily Wittbrodt, Eric Barone, Salvatore Chen, Hungta Sanchez, Juan Jose Garcia Järbrink, Krister Arnold, Matthew Tangri, Navdeep Clin Kidney J Original Article BACKGROUND: Timely diagnosis and treatment of stage 3 chronic kidney disease (CKD) can prevent further loss of kidney function and progression to kidney failure. However, contemporary data on the global prevalence of undiagnosed stage 3 CKD are scarce. REVEAL-CKD is a multinational, multifocal and observational study aiming to provide insights into undiagnosed stage 3 CKD in a large population. METHODS: Patients (aged ≥18 years) with data in selected secondary databases from 11 countries will be included if they have at least two estimated glomerular filtration rate (eGFR) measurements from 2015 onwards that are ≥30 and <60 mL/min/1.73 m(2), recorded >90 and ≤730 days apart. Undiagnosed cases are those without an International Classification of Diseases 9/10 diagnosis code for CKD (any stage) any time before and up to 6 months after the second qualifying eGFR measurement. Time to diagnosis will be assessed using a Kaplan–Meier approach; patient characteristics associated with undiagnosed CKD will be assessed using adjusted logistical regression analyses. RESULTS: REVEAL-CKD will assess the point prevalence of undiagnosed stage 3 CKD and time to CKD diagnosis in initially undiagnosed cases overall and in individual countries. Trends in undiagnosed CKD prevalence by calendar year will be assessed. Patient characteristics, healthcare resource utilization, adverse clinical outcomes, and CKD management and monitoring practices in patients with versus without a CKD diagnosis will be compared. CONCLUSIONS: REVEAL-CKD will increase awareness of the global clinical and economic burden of undiagnosed stage 3 CKD and provide valuable insights to inform clinical practice and policy changes. Oxford University Press 2021-12-16 /pmc/articles/PMC8967537/ /pubmed/35371463 http://dx.doi.org/10.1093/ckj/sfab235 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Kushner, Pamela Peach, Emily Wittbrodt, Eric Barone, Salvatore Chen, Hungta Sanchez, Juan Jose Garcia Järbrink, Krister Arnold, Matthew Tangri, Navdeep Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study |
title | Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study |
title_full | Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study |
title_fullStr | Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study |
title_full_unstemmed | Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study |
title_short | Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study |
title_sort | investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the reveal-ckd study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967537/ https://www.ncbi.nlm.nih.gov/pubmed/35371463 http://dx.doi.org/10.1093/ckj/sfab235 |
work_keys_str_mv | AT kushnerpamela investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy AT peachemily investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy AT wittbrodteric investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy AT baronesalvatore investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy AT chenhungta investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy AT sanchezjuanjosegarcia investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy AT jarbrinkkrister investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy AT arnoldmatthew investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy AT tangrinavdeep investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy |